“The same was in neuro intervention for aneurysms, it was open clipping or it was endovascular. And I think that’s what’s happening in BCI. So there’s a bunch of craniotomy-based, open BCI companies, and then there’s an interventional approach”, Synchron’s founder and CEO Tom Oxley explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Tom sits down with BI analyst Matt Henriksson for an in-depth interview about the company and how he utilized his experience with minimally invasive endovascular procedures to create its Stentrode as novel way to utilize brain-computer interfaces (BCI) without open brain surgery.

See omnystudio.com/listener for privacy information.